The number of deals signed by biopharma start-ups increased 7% in 2014, which featured a bump in partnerships for infectious disease drugs and multiple option-to-acquire agreements.
Biopharma start-ups continued the active pace of dealmaking in 2014, which featured a notable bump in partnerships for infectious disease programs, as well as some structured agreements built with options to acquire down the road.
In terms of overall volume, start-ups (which we define as companies that have been founded in the last four years)...
Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.
After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”
Even though the company’s pharmaceutical business continues to do well, navigating some key stress points will be crucial for Bayer.
